December 28, 2015
Jochen Gann BI’s first director of Hikma
Hikma Board has appointed Dr. Jochen Gann as BI’s first nominated director.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
December 22, 2015
Glenmark’s Linezolid, version of Pfizer’s Zyvox, gets nod from FDA
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Linezolid Tablets, 600 mg, the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, Inc.
December 22, 2015
FDA approves India’s Aurobindo’s generic version of Alcon’s Patanol
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% which makes the product is ready for launch.
December 22, 2015
Janssen and Bavarian Nordic to develop vaccine for Chronic Human Papillomavirus (HPV) infections
Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.
December 21, 2015
Martin Shkreli attributes arrest to drug-price hikes – WSJ
Martin Shkreli, the pharmaceutical entrepreneur facing U.S. charges of securities fraud, has said he had been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona
December 18, 2015
Managerial changes for Parabolic Drugs Limited
Indian pharmaceutical company Parabolic Drugs Limited has made certain changes to its board of directors. Namely, the company announced on…
December 17, 2015
Bristol’s drug pricing under fire as UK agency rejects Opdivo
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
December 17, 2015
Lilly’s and Boehringer Ingelheim’s insuline injection gets FDA’s nod
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.
December 16, 2015
AstraZeneca divests Entocort US rights to Perrigo for $380M
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
December 16, 2015
Lilly welcomes new board member
Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.